StreetInsider.com News Articles

Neurocrine Bio. (NBIX) PT Raised to $200 at Wells Fargo

Fri, 17 Jul 2026 06:42:07 -0400

Wells Fargo analyst Mohit Bansal raised the price target on Neurocrine Bio. (NASDAQ: NBIX) to $200.00 (from $175.00) while maintaining a Overweight rating.

Form 4 NEUROCRINE BIOSCIENCES For: Jul 07 Filed by: Delaet Ingrid

Wed, 15 Jul 2026 11:53:00 -0400

si-local-file:///var/storage/secattach/20260715/26772936.html

Form 4 NEUROCRINE BIOSCIENCES For: Jul 07 Filed by: Delaet Ingrid

Wed, 15 Jul 2026 11:53:00 -0400

si-local-file:///var/storage/secattach/20260715/26772936.html

Form 4 NEUROCRINE BIOSCIENCES For: Jul 10 Filed by: Delaet Ingrid

Mon, 13 Jul 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260713/26762762.html

Form 4 NEUROCRINE BIOSCIENCES For: Jul 10 Filed by: Delaet Ingrid

Mon, 13 Jul 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260713/26762762.html

Form 4 NEUROCRINE BIOSCIENCES For: Jul 09 Filed by: Lippoldt Darin

Mon, 13 Jul 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260713/26762749.html

Form 4 NEUROCRINE BIOSCIENCES For: Jul 09 Filed by: Lippoldt Darin

Mon, 13 Jul 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260713/26762749.html

Neurocrine Bio. (NBIX) PT Raised to $200 at Truist Securities

Mon, 13 Jul 2026 07:41:44 -0400

(Updated - July 13, 2026 7:41 AM EDT)

Truist Securities analyst Danielle Brill raised the price target on Neurocrine Bio. (NASDAQ: NBIX) to $200.00 (from $155.00) while maintaining a Buy rating.

The analyst commented: "NBIX (Buy; PT raised to $200 from $155). We expect 2Q26 results to beat expectations and drive a FY26 guidance raise, supported by favorable seasonal trends and continued strength in Ingrezza prescriptions. However, with shares up >30% over the past 3-months, we believe investors are already anticipating a beat-and-raise quarter, raising the bar for a meaningful positive stock reaction. While we

Neurocrine Bio. (NBIX) PT Raised to $200 at Truist Securities

Mon, 13 Jul 2026 07:41:44 -0400

(Updated - July 13, 2026 7:41 AM EDT)

Truist Securities analyst Danielle Brill raised the price target on Neurocrine Bio. (NASDAQ: NBIX) to $200.00 (from $155.00) while maintaining a Buy rating.

Neurocrine Bio. (NBIX) PT Raised to $170 at BMO Capital

Mon, 13 Jul 2026 07:34:56 -0400

BMO Capital analyst Evan David Seigerman raised the price target on Neurocrine Bio. (NASDAQ: NBIX) to $170.00 (from $144.00) while maintaining a Market Perform rating.

Form 144 NEUROCRINE BIOSCIENCES Filed by: Delaet Ingrid

Fri, 10 Jul 2026 16:39:00 -0400

si-local-file:///var/storage/secattach/20260710/26757761.html

Form 144 NEUROCRINE BIOSCIENCES Filed by: Delaet Ingrid

Fri, 10 Jul 2026 16:39:00 -0400

si-local-file:///var/storage/secattach/20260710/26757761.html

Form 4 NEUROCRINE BIOSCIENCES For: Jul 07 Filed by: Delaet Ingrid

Thu, 09 Jul 2026 18:41:00 -0400

si-local-file:///var/storage/secattach/20260709/26754106.html

Form 4 NEUROCRINE BIOSCIENCES For: Jul 07 Filed by: Delaet Ingrid

Thu, 09 Jul 2026 18:41:00 -0400

si-local-file:///var/storage/secattach/20260709/26754106.html

Form 144 NEUROCRINE BIOSCIENCES Filed by: Lippoldt Darin

Thu, 09 Jul 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260709/26753529.html

Form 144 NEUROCRINE BIOSCIENCES Filed by: Lippoldt Darin

Thu, 09 Jul 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260709/26753529.html

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results

Thu, 09 Jul 2026 16:01:00 -0400

Conference Call and Webcast Scheduled for Thursday, July 30

SAN DIEGO, July 9, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its second quarter 2026 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on July 30, 2026.

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results

Thu, 09 Jul 2026 16:01:00 -0400

Conference Call and Webcast Scheduled for Thursday, July 30

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results

Thu, 09 Jul 2026 16:01:00 -0400

Conference Call and Webcast Scheduled for Thursday, July 30

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results

Thu, 09 Jul 2026 16:01:00 -0400

Conference Call and Webcast Scheduled for Thursday, July 30

Form 144 NEUROCRINE BIOSCIENCES Filed by: Delaet Ingrid

Tue, 07 Jul 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260707/26742218.html

Form 144 NEUROCRINE BIOSCIENCES Filed by: Delaet Ingrid

Tue, 07 Jul 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260707/26742218.html

Neurocrine Bio. (NBIX) PT Raised to $195 at RBC Capital

Tue, 07 Jul 2026 07:55:29 -0400

RBC Capital analyst Brian Abrahams raised the price target on Neurocrine Bio. (NASDAQ: NBIX) to $195.00 (from $183.00) while maintaining a Outperform rating.

Neurocrine starts CAH drug trial in children under age 4

Wed, 01 Jul 2026 16:05:17 -0400

Neurocrine Biosciences (NASDAQ: NBIX) has initiated a Phase 2 clinical study to evaluate the safety and tolerability of crinecerfont in children aged 3 months to under 4 years with classic congenital adrenal hyperplasia (CAH), according to a company statement.

The open-label, single-arm study will enroll 20 participants over a 24-week treatment period. Secondary objectives include evaluating the pharmacokinetics and pharmacodynamic effects of crinecerfont on hormone biomarkers. The study is being conducted under an FDA Pediatric Written Request.

Crinecerfont, marketed as Crenessity, was approved by the U.S. Food and Drug Administration in 2024 as an adjunctive treatment to glucocorticoid replacement for adults and

Neurocrine starts CAH drug trial in children under age 4

Wed, 01 Jul 2026 16:05:17 -0400

Crinecerfont, marketed as Crenessity, was approved by the U.S. Food and Drug Administration in 2024 as an adjunctive treatment to glucocorticoid replacement for adults and